PURPOSE: The background and methods of an ongoing study to determine the effects of hospital pharmacists' enhanced communication with patients and their community providers are described. SUMMARY: The Iowa Continuity of Care study is a randomized, prospective trial enrolling 1000 patients with selected medical conditions admitted to one large Midwest hospital. Patients will be randomized to a control group (usual care), minimal intervention, or enhanced intervention. For the intervention groups, a pharmacist case manager (PCM) will provide admission medication verification with the patients' community pharmacists, medication teaching, and discharge counseling. Patients in the enhanced intervention group will have a discharge care plan faxed to their outpatient physician and community pharmacist and will receive a follow-up phone call from the PCM three to five days after discharge; the PCM will continue to facilitate communication between the patient and community providers until all medication problems are resolved. A blinded research nurse will collect data, including adverse drug event (ADE) data, at admission and 30 and 90 days after discharge. The primary outcome measures include medication appropriateness, ADEs, emergency department visits, unscheduled office visits, and rehospitalizations. Data will be collected from the inpatient electronic medical record, outpatient physician medical records, and community pharmacist records and directly from patients. A cost-effectiveness analysis will be performed. CONCLUSION: This study will address the value of a PCM in improving communication of care plans between the inpatient and community settings and thereby optimizing medication use.
RCT Entities:
PURPOSE: The background and methods of an ongoing study to determine the effects of hospital pharmacists' enhanced communication with patients and their community providers are described. SUMMARY: The Iowa Continuity of Care study is a randomized, prospective trial enrolling 1000 patients with selected medical conditions admitted to one large Midwest hospital. Patients will be randomized to a control group (usual care), minimal intervention, or enhanced intervention. For the intervention groups, a pharmacist case manager (PCM) will provide admission medication verification with the patients' community pharmacists, medication teaching, and discharge counseling. Patients in the enhanced intervention group will have a discharge care plan faxed to their outpatient physician and community pharmacist and will receive a follow-up phone call from the PCM three to five days after discharge; the PCM will continue to facilitate communication between the patient and community providers until all medication problems are resolved. A blinded research nurse will collect data, including adverse drug event (ADE) data, at admission and 30 and 90 days after discharge. The primary outcome measures include medication appropriateness, ADEs, emergency department visits, unscheduled office visits, and rehospitalizations. Data will be collected from the inpatient electronic medical record, outpatient physician medical records, and community pharmacist records and directly from patients. A cost-effectiveness analysis will be performed. CONCLUSION: This study will address the value of a PCM in improving communication of care plans between the inpatient and community settings and thereby optimizing medication use.
Authors: Glen T Schumock; Melissa G Butler; Patrick D Meek; Lee C Vermeulen; Bhakti V Arondekar; Jerry L Bauman Journal: Pharmacotherapy Date: 2003-01 Impact factor: 4.705
Authors: Jerry H Gurwitz; Terry S Field; Leslie R Harrold; Jeffrey Rothschild; Kristin Debellis; Andrew C Seger; Cynthia Cadoret; Leslie S Fish; Lawrence Garber; Michael Kelleher; David W Bates Journal: JAMA Date: 2003-03-05 Impact factor: 56.272
Authors: Tejal K Gandhi; Saul N Weingart; Joshua Borus; Andrew C Seger; Josh Peterson; Elisabeth Burdick; Diane L Seger; Kirstin Shu; Frank Federico; Lucian L Leape; David W Bates Journal: N Engl J Med Date: 2003-04-17 Impact factor: 91.245
Authors: Elizabeth A Chrischilles; Barry L Carter; Brian C Lund; Linda M Rubenstein; Shari S Chen-Hardee; Margaret D Voelker; Tae-Ryong Park; Angela K Kuehl Journal: J Am Pharm Assoc (2003) Date: 2004 May-Jun
Authors: Gayle A Brazeau; Susan M Meyer; Michele Belsey; Edward M Bednarczyk; Sanela Bilic; Julie Bullock; Gary E DeLander; E F Fiese; Stephen L Giroux; Danny McNatty; Ruth Nemire; William A Prescott; Andrew P Traynor Journal: Am J Pharm Educ Date: 2009-12-17 Impact factor: 2.047
Authors: Daniela C Gonçalves-Bradley; Natasha A Lannin; Lindy M Clemson; Ian D Cameron; Sasha Shepperd Journal: Cochrane Database Syst Rev Date: 2016-01-27
Authors: Sammuel V Anderegg; David E Demik; Barry L Carter; Jeffrey D Dawson; Karen Farris; Constance Shelsky; Peter Kaboli Journal: Pharmacotherapy Date: 2013-01 Impact factor: 4.705
Authors: Karen B Farris; Barry L Carter; Yinghui Xu; Jeffrey D Dawson; Constance Shelsky; David B Weetman; Peter J Kaboli; Paul A James; Alan J Christensen; John M Brooks Journal: BMC Health Serv Res Date: 2014-09-18 Impact factor: 2.655